Use of plasma proteins as solubilizing agents in in vitro permeability experiments: Correction for unbound drug concentration using the reciprocal permeability approach

Journal of Pharmaceutical Sciences

Volumn 97, Issue 1, 2008, Pages 209-224

  Katneni, Kasiram ^a   Charman, Susan A ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Absorption; In vitro models; Intestinal epithelia; P glycoprotein; Permeability; Protein binding; Solubility

Indexed keywords

ALBUMIN; DIAZEPAM; DIGOXIN; OROSOMUCOID; PLASMA PROTEIN; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BINDING; DRUG EFFECT; DRUG PENETRATION; DRUG SOLUBILITY; IN VITRO STUDY; INTESTINE EPITHELIUM; NONHUMAN; PROTEIN DEPLETION; RAT; THERMODYNAMICS;

EID: 38349127393     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20877     Document Type: Article

References (60)

1. Krishna G, Chen K, Lin C, Nomeir AA. 2001. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int J Pharm 222:77-89.
2. Unger JK, Kuehlein G, Schroers A, Gerlach JC, Rossaint R. 2001. Adsorption of xenobiotics to plastic tubing incorporated into dynamic in vitro systems used in pharmacological research-limits and progress. Biomaterials 22:2031-2037.
3. Palmgren JJ, Monkkonen J, Korjamo T, Hassinen A, Auriola S. 2006. Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm 64:369-378.
4. Rege BD, Yu LX, Hussain AS, Polli JE. 2001. Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci 90:1776-1786.
5. Saha P, Kou JH. 2000. Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers. Eur J Pharm Biopharm 50:403-411.
6. Lindberg BF, Andersson KE. 1991. Adsorption of atrial natriuretic peptide to different materials: A factor influencing results of in vitro experiments? Pharmacol Toxicol 68:276-281.
7. Nerurkar MM, Ho NF, Burton PS, Vidmar TJ, Borchardt RT. 1997. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J Pharm Sci 86:813-821.
8. Shono Y, Nishihara H, Matsuda Y, Furukawa S, Okada N, Fujita T, Yamamoto A. 2004. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci 93:877-885.
9. Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. 2002. Tacrolimus is a class II low-solubility high-permeability drug: The effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 91:719-729.
10. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R, Coffin M. 1999. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res 16:1812-1817.
11. Katneni K, Charman SA, Porter CJH. 2006. Permeability assessment of poorly water soluble compounds under solubilizing conditions: The reciprocal permeability approach. J Pharm Sci 95:2170-2185.
12. Miller DW, Batrakova EV, Kabanov AV. 1999. Inhibition of multidrug resistance-associated protein (MRP) functional activity with pluronic block copolymers. Pharm Res 16:396-401.
13. Katneni K, Charman SA, Porter CJH. 2007. Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: Delineation of thermodynamic and transporter related events using the reciprocal permeability approach. J Pharm Sci 96:280-293.
14. Zhang H, Yao M, Morrison RA, Chong S. 2003. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 26:768-772.
15. Varma MV, Panchagnula R. 2005. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 25:445-453.
16. Rege BD, Kao JP, Polli JE. 2002. Effects of nonionic Surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16:237-246.
17. Neuhoff S, Artursson P, Zamora I, Ungell AL. 2006. Impact of extracellular protein binding on passive and active drug transport across, caco-2 cells. Pharm Res 23:350-359.
18. Artursson P. 1990. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 79:476-482.
19. Saha P, Kou JH. 2002. Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. Eur J Pharm Biopharm 54:319-324.
20. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H. 2000. Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10:195-204.
21. Sawada GA, Barsuhn CL, Lutzke BS, Houghton ME, Padbury GE, Ho NF, Raub TJ. 1999. Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants. J Pharmacol Exp Ther 288:1317-1326.
22. Cross SE, Anissimov YG, Magnusson BM, Roberts MS. 2003. Bovine-serum-albumin-containing receptor phase better predicts transdermal absorption parameters for lipophilic compounds. J Invest Dermatol 120:589-591.
23. Youdim KA, Avdeef A, Abbott NJ. 2003. In vitro trans-monolayer permeability calculations: Often forgotten assumptions. Drug Discov Today 8:997-1003.
24. Ho NFH, Raub TJ, Burton PS, Barsuhn PL, Adson A, Audus KL, Borchardt RT. 2000. Quantitative approaches to delineate passive transport mechanisms in cell culture monolayers. New York: Mercel Dekker. 102:219-316.
25. Aungst BJ, Nguyen NH, Bulgarelli JP, Oates-Lenz K. 2000. The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm Res 17:1175-1180.
26. Sawada GA, Ho NF, Williams LR, Barsuhn CL, Raub TJ. 1994. Transcellular permeability of chlorpromazine demonstrating the roles of protein binding and membrane partitioning. Pharm Res 11:665-673.
27. Shargel L, Yu BCA. 1993. Applied biopharmaceutics and pharmacokinetics. 3rd edition. Norwalk, Connecticut: Appleton & Lange. pp 594-595.
28. Stephens RH, Tanianis-Hughes J, Higgs NB, Humphrey M, Warhurst G. 2002. Region-dependent modulation of intestinal permeability by drug efflux transporters: In vitro studies in mdr1a(-/-) mouse intestine. J Pharmacol Exp Ther 303:1095-1101.
29. Cogburn JN, Donovan MG, Schasteen CS. 1991. A model of human small intestinal absorptive cells. 1. Transport barrier. Pharm Res 8:210-216.
30. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. 2006. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metab Dispos 34:786-792.
31. Johansen AK, Willassen NP, Sager G. 1992. Fluorescence studies of beta-adrenergic ligand binding to alpha 1-acid glycoprotein with 1-anilino-8-naphthalene sulfonate, isoprenaline, adrenaline and propranolol. Biochem Pharmacol 43:725-729.
32. Dufour C, Dangles O. 2005. Flavonoid-serum albumin complexation: Determination of binding constants and binding sites by fluorescence spectroscopy. Biochim Biophys Acta 1721:164-173.
33. Lukas DS, De Martino AG. 1969. Binding of digitoxin and some related cardenolides to human plasma proteins. J Clin Invest 48:1041-1053.
34. Ding Y, Zhu X, Lin B. 1999. Investigation of association parameters of basic drugs to human serum albumin by capillary zone electrophoresis/frontal analysis. Se Pu 17:58-60.
35. Hanada K, Ohta T, Hirai M, Arai M, Ogata H. 2000. Enantioselective binding of propranolol, disopyramide, and verapamil to human alpha(1)-acid glycoprotein. J Pharm Sci 89:751-757.
36. Brunner F, Muller WE. 1987. The stereoselectivity of the 'single drug binding site' of human alpha 1-acid glycoprotein (orosomucoid). J Pharm Pharmacol 39:986-990.
37. Hansen T, Borlak J, Bader A. 2000. Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica 30:27-46.
38. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50:S41-S67.
39. Lo MW, Effeney DJ, Pond SM, Silber BM, Riegelman S. 1982. Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition. J Pharmacol Exp Ther 221:512-515.
40. Mills PC, Siebert GA, Roberts MS. 2004. A model to study intestinal and hepatic metabolism of propranolol in the dog. J Vet Pharmacol Ther 27:45-48.
41. Shand DG, Rangno RE. 1972. The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology 7:159-168.
42. Caldwell JH, Caldwell PB, Murphy JW, Beachler CW. 1980. Intestinal secretion of digoxin in the rat. Augmentation by feeding activated charcoal. Naunyn Schmiedebergs Arch Pharmacol 312:271-275.
43. Liu S, Tam D, Chen X, Pang KS. 2006. P-glycoprotein and an unstirred water layer barring digoxin absorption in the vascularly perfused rat small intestine preparation: Induction studies with pregnenolone-16alpha-carbonitrile. Drug Metab Dispos 34:1468-1479.
44. Johnson BM, Charman WN, Porter CJ. 2002. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS Pharm Sci 4:E40.
45. Ungell AL, Andreasson A, Lundin K, Utter L. 1992. Effects of enzymatic inhibition and increased paracellular shunting on transport of vasopressin analogues in the rat. J Pharm Sci 81:640-645.
46. Wan H, Ostlund A, Jonsson S, Lindberg W. 2005. Single run measurements of drug-protein binding by high-performance frontal analysis capillary electrophoresis and mass spectrometry. Rapid Commun Mass Spectrom 19:1603-1610.
47. Wright JD, Boudinot FD, Ujhelyi MR. 1996. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 30:445-462.
48. Di L, Kerns EH. 2003. Profiling drug-like properties in discovery research. Curr Opin Chem Biol 7:402-408.
49. Stoner CL, Cleton A, Johnson K, Oh DM, Hallak H, Brodfuehrer J, Surendran N, Han HK. 2004. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery. Int J Pharm 269:241-249.
50. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26.
51. Copeland RA. 2000. Enzymes: A practical Introduction to structure, mechanism and data analysis. 2nd ed. New York: Wiley-VCH, Inc. pp 76-108.
52. Kenakin T. 1997. Pharmacologic analysis of drug-receptor interaction. 3rd edition. Philadelphia, New York: Lippincott-Raven Publishers. pp 255-256.
53. Connors KA. 2002. Thermodynamics of pharmaceutical systems: An introduction for students of pharmacy. Hoboken, NJ: John Wiley & Sons, Inc. pp 237-257.
54. Lee KJ, Mower R, Hollenbeck T, Castelo J, Johnson N, Gordon P, Sinko PJ, Holme K, Lee YH. 2003. Modulation of nonspecific binding in ultrafiltration protein binding studies. Pharm Res 20:1015-1021.
55. Taylor S, Harker A. 2006. Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal 41:299-303.
56. Gillis AM, Yee YG, Kates RE. 1985. Binding of anti-arrhythmic drugs to purified human alpha 1-acid glycoprotein. Biochem Pharmacol 34:4279-4282.
57. Antonov YA, Wolf BA. 2005. Calorimetric and structural investigation of the interaction between bovine serum albumin and high molecular weight dextran in water. Biomacromolecules 6:2980-2989.
58. Tamura K, Yatsu T, Itoh H, Motoi Y. 1989. Isolation, characterization, and quantitative measurement of serum alpha 1-acid glycoprotein in cattle. Nippon Juigaku Zasshi 51:987-994.
59. Chauvelot-Moachon L, Tallet F, Durlach-Misteli C, Giroud JP. 1988. Delipidation of alpha 1-acid glycoprotein. Propranolol binding to this glycoprotein and its modification by extracted material and exogenous lipids. J Pharmacol Methods 20:15-28.
60. Primozic S, McNamara PJ. 1985. Effect of the sialylation state of alpha 1-acid glycoprotein on propranolol binding. J Pharm Sci 74:473-475.